Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects

BACKGROUND AND OBJECTIVE: Vidofludimus is a potent and selective inhibitor of human mitochondrial enzyme dihydroorotate dehydrogenase (DHODH). The clinical efficacy and safety profile of vidofludimus has been analyzed in patients suffering from rheumatoid arthritis and Crohn’s disease and ulcerative...

Descripción completa

Detalles Bibliográficos
Autores principales: Muehler, Andreas, Kohlhof, Hella, Groeppel, Manfred, Vitt, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511286/
https://www.ncbi.nlm.nih.gov/pubmed/32361977
http://dx.doi.org/10.1007/s13318-020-00623-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511286/
https://www.ncbi.nlm.nih.gov/pubmed/32361977
http://dx.doi.org/10.1007/s13318-020-00623-7

Ejemplares similares